Evidence map›Paper›PMID 16051701›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2005

Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain.

Dhruba J Bharali, Ilona Klejbor, Ewa K Stachowiak, Purnendu Dutta, Indrajit Roy, Navjot Kaur, Earl J Bergey, Paras N Prasad, Michal K Stachowiak

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 141 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
141citing papers in PubMed, 2 pooled it
11.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

141 citing papers in PubMed, 2 syntheses or guidelines pooled it, 619 citations in OpenAlex.

  1. Pooled it
  2. Intrathecal drug delivery in the era of nanomedicine.Advanced drug delivery reviews · 2020
    Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. An Overview of Methods and Tools for Transfection of Eukaryotic CellsFrontiers in bioengineering and biotechnology · 2021
    Review
  19. Review
  20. Review

81 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Dhruba J BharaliInstitute for Lasers, Photonics, and Biophotonics, Department of Chemistry, State University of New York, Buffalo, NY 14260, USA.
Ilona Klejbor
Ewa K Stachowiak
Purnendu Dutta
Indrajit Roy
Navjot Kaur
Earl J Bergey
Paras N Prasad
Michal K Stachowiak
Gdańsk Medical University · PLUniversity at Buffalo, State University of New York · US

Funding

Defective nuclear FGFR1 signaling - a new model for PDR21NS043621 · NINDS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI STACHOWIAK, MICHAL · 2002 to 2003
$389k
NINDS NIH HHS NS43621NINDS NIH HHS NS43621-01NINDS NIH HHS R21 NS043621
6 · The paper itself

Abstract

This article reports on the application of organically modified silica (ORMOSIL) nanoparticles as a nonviral vector for efficient in vivo gene delivery. Highly monodispersed, stable aqueous suspension of nanoparticles, surface-functionalized with amino groups for binding of DNA, were prepared and characterized. Stereotaxic injections of nanoparticles, complexed with plasmid DNA encoding for EGFP, into the mouse ventral midbrain and into lateral ventricle, allowed us to fluorescently visualize the extensive transfection of neuronal-like cells in substantia nigra and areas surrounding the lateral ventricle. No ORMOSIL-based toxicity was observed 4 weeks after transfection. The efficiency of transfection equaled or exceeded that obtained in studies using a viral vector. An in vivo optical imaging technique (a fiber-based confocal fluorescent imaging system) provided an effective means to show the retention of viability of the transfected cells. The ORMOSIL-mediated transfections also were used to manipulate the biology of the neural stem/progenitor cells in vivo. Transfection of a plasmid expressing the nucleus-targeting fibroblast growth factor receptor type 1 resulted in significant inhibition of the in vivo incorporation of bromodeoxyuridine into the DNA of the cells in the subventricular zone and the adjacent rostral migratory stream. This in vivo approach shows that the nuclear receptor can control the proliferation of the stem/progenitor cells in this region of the brain. The results of this nanomedicine approach using ORMOSIL nanoparticles as a nonviral gene delivery platform have a promising future direction for effective therapeutic manipulation of the neural stem/progenitor cells as well as in vivo targeted brain therapy.

Indexed as

Gene ExpressionNanostructuresAnimalsBrainBromodeoxyuridineCell ProliferationDNAGenetic TherapyGenetic VectorsGreen Fluorescent ProteinsMiceMicroscopy, ConfocalReceptor, Fibroblast Growth Factor, Type 1Silicon DioxideStem CellsTransfectionBromodeoxyuridineDNAenhanced green fluorescent proteinFgfr1 protein, ratGreen Fluorescent ProteinsReceptor, Fibroblast Growth Factor, Type 1Silicon Dioxide

Identifiers

PMID16051701
PMCPMC1181239
OpenAlexW2006986838

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.